ViroGates appoints Josephine Baum Jørgensen as its new Chief Financial Officer
No. 01-2023 – Inside Information - 1 February 2023
BIRKERØD, DENMARK – ViroGates A/S, a medical technology company developing blood tests for better triaging in hospitals to improve patient care and reduce healthcare costs, today announces that Josephine Baum Jørgensen will be joining ViroGates as the Company’s new CFO succeeding Mark da Silva.
Josephine is 31 years old and joins ViroGates from a position as Product Owner of the Holiday Allowance Fund at ATP. Josephine has previously worked as a Chief Adviser at Økonomistyrelsen (the Agency for Public Finance and Management) and as a management consultant at Deloitte Consulting, where she has completed several projects within both public management, strategy, and business development.
Josephine holds an M.Sc. in Finance and Strategic Management from Copenhagen Business School. During her studies Josephine completed courses at both London School of Economics and Pontifícia Universidade Católica do Rio de Janeiro.
Josephine will lead the CFO function with a focus on strategy development and execution, reporting and finance as well as working with the sales and marketing team to improve processes in ViroGates’ various sales channels. Josephine will co-manage ViroGates’ investor relations activities with CEO Jakob Knudsen.
Josephine will join ViroGates on 13th March 2023 and will become part of the Company’s management team.
Josephine Baum Jørgensen says: “I am very excited to join ViroGates and contribute to strengthening the company’s position through strategic development as well as supporting the continuing sales efforts to Acute care facilities. I believe ViroGates can be a key player in adapting to the conditions that characterize healthcare systems today. I am looking forward to embarking on the journey with the excellent team."
CEO Jakob Knudsen, says in a comment: ”I am delighted that Josephine will be joining our team here at ViroGates. Josephine has an excellent skill set to complement and build on ongoing work, as well as a personality that I believe will fit well with the rest of the organisation. I look forward to working with Josephine to shape ViroGates for the next steps in our commercial journey.”
For further information, please contact:
CEO, Jakob Knudsen
Tel. (+45) 2226 1355, email: [email protected]
Västra Hamnen Corporate Finance
Tel. (+46) 40 200 250, email: [email protected]
ViroGates A/S is an international medical technology company developing and marketing blood test products under the suPARnostic® brand for better triaging in hospitals to improve patient care, reduce healthcare costs and empower clinical staff.
The company was founded in 2000. Headquartered in Denmark, ViroGates’ sales force covers the Nordics, Spain, and France, while distributors serve other markets. ViroGates’ shares (VIRO) are listed on Nasdaq First North Growth Market Denmark. For more information, please visit www.virogates.com.
About suPAR and suPARnostic®
suPAR is the biomarker detected by ViroGates’ suPARnostic® products and is a protein in plasma, measurable in every human being. suPAR is considered a general risk status biomarker indicating disease presence, disease severity and progression, organ damage and mortality risk across disease areas such as cardiovascular diseases, kidney diseases, type 2 diabetes, cancer, etc. Strong scientific evidence from more than 850 clinical trials and studies show that the higher the level of suPAR, the worse the prognosis for the patient.
The suPARnostic® products can be used to support healthcare professionals in making clinical decisions on hospitalization or discharge of acute care patients. The increasing demands on health systems globally and tightening healthcare budgets necessitate efficiency improvements and innovative solutions in hospitals. The use of suPAR in clinical routine in emergency departments can improve patient care and reduce healthcare costs by increasing the number of discharges by up to 34% and reducing the average hospital length-of-stay by up to 6% without affecting mortality. suPARnostic® TurbiLatex is currently available on Roche Diagnostics’ cobas® instruments, Siemens Healthineers ADVIA® XPT and Atellica® instruments and the Abbott Labs Architect™ and Alinity™ instruments. ViroGates works with partners to develop solutions for other platforms.
Prospects about the future reflect ViroGates' current expectations for future events and results. The statements are by nature inherent in risks, uncertainties and other matters that are difficult to predict or out of control. The actual results may therefore differ from the expectations expressed.
- Jakob Knudsen, CEO, +45 2226 1355, [email protected]